Company Of The Day: Pfizer
What?
A recently published study from Israel on booster shots of Pfizer (NYSE:PFE) and its partner BioNTech’s Covid-19 vaccine indicates that a fourth dose of the vaccine (second booster) lowered the risk of severe disease in the elderly, although protection against infection was apparently short-lived.
So What?
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
The U.S. recently authorized a second booster for people aged 50 and older while Israel is offering the shot for people aged 60 years or older. The data could likely encourage people to come forward and get additional protection as new Covid-19 variants emerge.
See Our Complete Analysis For Pfizer
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Apr 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| PFE Return | 1% | -11% | 61% |
| S&P 500 Return | 0% | -5% | 102% |
| Trefis MS Portfolio Return | 0% | -8% | 262% |
[1] Month-to-date and year-to-date as of 4/7/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios